Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex

Journal of Neuroscience

Volumn 23, Issue 26, 2003, Pages 8836-8843

  González Maeso, Javier ^a   Yuen, Tony ^a   Ebersole, Barbara J ^a   Wurmbach, Elisa ^a   Lira, Alena ^b   Zhou, Mingming ^b   Weisstaub, Noelia ^b   Hen, Rene ^b   Gingrich, Jay A ^b   Sealfon, Stuart C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

5 HT2A receptor; Hallucinogen; LSD; Serotonin; Signal transduction; Somatosensory cortex

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; G PROTEIN COUPLED RECEPTOR; LISURIDE MALEATE; LYSERGIDE; SEROTONIN 2A AGONIST;

ANIMAL CELL; ARTICLE; BEHAVIOR; COGNITION; CONTROLLED STUDY; DRUG ABUSE; HALLUCINATION; HEAD TWITCH; MOUSE; NEUROPHARMACOLOGY; NONHUMAN; PERCEPTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOMATOSENSORY CORTEX; TASK PERFORMANCE;

EID: 0141753077     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.23-26-08836.2003     Document Type: Article

References (53)

1. Aghajanian GK, Marek GJ (1999a) Serotonin and hallucinogens. Neuropsychopharmacology 21:16S-23S.
2. 2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res 825:161-171.
3. Aghajanian GK, Marek GJ (2000) Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Brain Res Rev 31:302-312.
4. 2A receptors to inhibit NMDA receptor-mediated transmission in the rat prefrontal cortex. Eur J Neurosci 11:3064-3072.
5. Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38:1083-1152.
6. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94-104.
7. Cermakian N, Monaco L, Pando MP, Dierich A, Sassone-Corsi P (2001) Altered behavioral rhythms and clock gene expression in mice with a targeted mutation in the Period1 gene. EMBO J 20:3967-3974.
8. Clayton DF (2000) The genomic action potential. Neurobiol Learn Mem 74:185-216.
9. 2 dopamine receptor/G-protein interaction. Evidence for agonist selection of G-protein subtype. J Biol Chem 276:28667-28675.
10. 2C receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking. Mol Pharmacol 62:578-589.
11. 2A receptor determines relative efficacy. Mol Pharmacol 63:36-43.
12. 2C receptors. Psychopharmacology (Berl) 136:409-414.
13. 2C receptors in the stimulus effects of hallucinogenic drugs. I: Antagonist correlation analysis. Psychopharmacology (Berl) 121:347-356.
14. Gewirtz JC, Marek GJ (2000) Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology 23:569-576.
15. Gewirtz JC, Chen AC, Terwilliger R, Duman RC, Marek GJ (2002) Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors. Pharmacol Biochem Behav 73:317-326.
16. 2A receptor are insensitive to many of the behavioral and physiological effects of hallucinogens. Soc Neurosci Abstr 25:799.
17. Gresch PJ, Strickland LV, Sanders-Bush E (2002) Lysergic acid diethylamide-induced Fos expression in rat brain: role of serotonin-2A receptors. Neuroscience 114:707-713.
18. Hill SJ, Baker JG, Rees S (2001) Reporter-gene systems for the study of G-protein-coupled receptors. Curr Opin Pharmacol 1:526-532.
19. Impey S, Mark M, Villacres EC, Poser S, Chavkin C, Storm DR (1996) Induction of CRE-mediated gene expression by stimuli that generate long-lasting LTP in area CA1 of the hippocampus. Neuron 16:973-982.
20. Jakab RL, Goldman-Rakic PS (1998) 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci USA 95:735-740.
21. Jordan JD, Landau EM, Iyengar R (2000) Signaling networks: the origins of cellular multitasking. Cell 103:193-200.
22. Kenakin T (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232-238.
23. Kenakin T (1997) Differences between natural and recombinant G-protein-coupled receptor systems with varying receptor/G-protein stoichiometry. Trends Pharmacol Sci 18:456-464.
24. Lambe EK, Aghajanian GK (2001) The role of Kv1.2-containing potassium channels in serotonin-induced glutamate release from thalamocortical terminals in rat frontal cortex. J Neurosci 21:9955-9963.
25. Langlois MC, Beaudry G, Zekki H, Rouillard C, Levesque D (2001) Impact of antipsychotic drug administration on the expression of nuclear receptors in the neocortex and striatum of the rat brain. Neuroscience 106:117-128.
26. 3H]MDL 100,907. Naunyn Schmiedebergs Arch Pharmacol 356:446-454.
27. 2A receptors are labeled by agonists and discriminated by antagonists. Mol Pharmacol 60:690-699.
28. Marek GJ, Wright RA, Gewirtz JC, Schoepp DD (2001) A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex. Neuroscience 105:379-392.
29. Marona-Lewicka D, Kurrasch-Orbaugh DM, Selken JR, Cumbay MG, Lisnicchia JG, Nichols DE (2002) Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats. Psychopharmacology (Berl) 164:93-107.
30. Martin-Ruiz R, Puig MV, Celada P, Shapiro DA, Roth BL, Mengod G, Artigas F (2001) Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurosci 21:9856-9866.
31. Meltzer HY (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21:106S-115S.
32. Mokler DJ, Rech RH (1984) Behavioral effects of intracerebroventricular administration of LSD, DOM, mescaline or lisuride. Pharmacol Biochem Behav 21:281-287.
33. Nichols DE (1997) Role of serotoninergic neurons and 5-HT receptors in the action of hallucinogens. In: Serotoninergic neurons and 5-HT receptors in the CNS (Baumgarten HG, Gothert M, eds), pp 563-585. Berlin: Springer.
34. 2 adrenergic receptor: observation of conformational substates in a membrane protein. Proc Natl Acad Sci USA 98:8469-8474.
35. Pieri L, Keller HH, Burkard W, Da Prada M (1978) Effects of lisuride and LSD on cerebral monoamine systems and hallucinosis. Nature 272:278-280.
36. 2C receptors in CHO-K1 cells. Br J Pharmacol 128:13-20.
37. 2C receptor: identification of a novel "locked-on" phenotype and double revertant mutations. J Biol Chem 277:36577-36584.
38. 2A heteroceptors on thalamocortical glutamatergic neurons. J Neurosci 20:8846-8852.
39. Shaffer JP (1995) Multiple hypothesis testing. Annu Rev Psychol 46:561-584.
40. 2A receptor-enhanced excitatory postsynaptic currents in layer V neurons of the rat medial prefrontal cortex. Neuroscience 105:55-69.
41. Vaidya VA, Marek GJ, Aghajanian GK, Duman RS (1997) 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci 17:2785-2795.
42. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 9:3897-3902.
43. West WB, Lou A, Pechersky K, Chachich ME, Appel JB (2000) Antagonism of a PCP drug discrimination by hallucinogens and related drugs. Neuropsychopharmacology 22:618-625.
44. White FJ, Appel JB (1982) Lysergic acid diethylamide (LSD) and lisuride: differentiation of their neuropharmacological actions. Science 216:535-537.
45. Willins DL, Meltzer HY (1997) Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther 282:699-706.
46. Winslow JT, Miczek KA (1983) Habituation of aggression in mice: pharmacological evidence of catecholaminergic and serotonergic mediation. Psychopharmacology (Berl) 81:286-291.
47. Wirz-Justice A, Haug HJ, Cajochen C (2001) Disturbed circadian rest-activity cycles in schizophrenia patients: an effect of drugs? Schizophr Bull 27:497-502.
48. Wurmbach E, Yuen T, Ebersole BJ, Sealfon SC (2001) Gonadotropin-releasing hormone receptor-coupled gene network organization. J Biol Chem 276:47195-47201.
49. Wurmbach E, Gonzalez-Maeso J, Yuen T, Ebersole BJ, Mastaitis JW, Mobbs CV, Sealfon SC (2002) Validated genomic approach to study differentially expressed genes in complex tissues. Neurochem Res 27:1027-1033.
50. Yuen T, Zhang W, Ebersole BJ, Sealfon SC (2002a) Monitoring G-protein-coupled receptor signaling with DNA microarrays and real-time polymerase chain reaction. Methods Enzymol 345:556-569.
51. Yuen T, Wurmbach E, Pfeffer RL, Ebersole BJ, Sealfon SC (2002b) Accuracy and calibration of commercial oligonucleotide and custom cDNA microarrays. Nucleic Acids Res 30:e48.
52. Yuen T, Wurmbach E, Ebersole BJ, Ruf F, Pfeffer RL, Sealfon SC (2002c) Coupling of GnRH concentration and the GnRH receptor-activated gene program. Mol Endocrinol 16:1145-1153.
53. 2 receptor: a mechanistic hypothesis from molecular dynamics simulations of the three-dimensional model of the receptor complexed to ligands. J Med Chem 36:934-938.